Background: The goal of this study was to determine a predominant cell type expressing fractalkine receptor (CX 3 CR1) in mature ovarian teratomas and to establish functional significance of its expression in cell differentiation. Methods: Specimens of ovarian teratoma and human fetal tissues were analyzed by immunohistochemistry for CX 3 CR1expression. Ovarian teratocarcinoma cell line PA-1 was used as a model for cell differentiation.
Fractalkine receptor is expressed in mature ovarian teratomas and required for epidermal lineage differentiation Background Ovarian teratoma (dermoid cyst) is a benign tumor originating in germ cells. This tumor is one of the most common germ cell tumors and accounts for up to 20% of all ovarian cysts [1] . Ovarian teratoma is the most common tumor associated with pregnancy [2] . Generally, ovarian teratomas are cured by a complete surgical resection; however, some cases could give rise to a malignant disease [3, 4] . Ovarian teratomas could be of both homozygous and heterozygous origin, as well as the mixture of the two, and it has been previously suggested that several mechanisms could lead to their development, including failure of meiosis I, failure of meiosis II, or duplication of a mature ovum [5] . Mature ovarian teratomas often contain a mixture of fully differentiated tissues from all three cell layers, ectodermal, endodermal, and mesodermal, resulting in formation of skin, hair follicle, sebaceous gland, bone, teeth, thyroid, and other cell types [6, 7] .
Our previous data obtained using a limited number of subjects suggested that a chemokine receptor fractalkine (CX 3 CR1) is expressed in ovarian teratomas [8] . CX 3 CR1 is a G protein-coupled receptor with multiple functions in both the normal state and disease [9, 10] . CX 3 CR1 is activated by its highly specific ligand fractalkine (CX 3 CL1) [11] . It has been shown that CX 3 CL1/CX 3 CR1 axis plays a role in differentiation of osteoclasts [12] and development of dendritic cells [13] , but its role in skin differentiation has not been described.
The goal of this study was to determine the predominant type of CX 3 CR1-positive cells in ovarian teratomas. We also aimed to determine whether the same cell type (s) are CX 3 CR1-positive during the normal development. Lastly, using a cell culture model, we intended to establish whether CX 3 CR1 expression is required for cell differentiation. 
Cell culture and directed differentiation
Ovarian teratocarcinoma cell line PA-1 and ovarian carcinoma cell line SKOV-3 were obtained from American Tissue Culture Collection (Manassas, VA). PA-1 cells were plated on Matrigel-coated (at 1/100 dilution) tissue culture plates or glass cover slips at 5% confluence and cultured in minimal essential media supplemented with sodium pyruvate and non-essential amino acids for 2 weeks. Cells subjected to differentiation into skin lineage were cultured in the above described media containing 10 μg/ml BMP-4.
Immunohistochemical staining
TMA slides were deparaffinized by baking at 60°C for 2 h and rehydrated by incubation in xylene, 100% ethanol, 95% ethanol, 70% ethanol, and phosphate buffered saline, pH 7.4, for 5 min each. Peroxidase activity was inhibited with hydrogen peroxide. Antigen retrieval was performed by 15 min incubation in 1 mM ethylene diamine tetraacetic acid (EDTA; pH 8.0) at 95°C. Prior to primary antibody staining (1:50 dilution, rabbit antihuman CX 3 CR1, Abcam Cat# ab8021, 1 h at room temperature (RT)) non-specific binding was blocked by incubation with 10% goat serum for 1 h. The biotinconjugated goat anti-rabbit secondary antibody was used at a 1:200 dilution for 30 min at RT. The Vectashield ABC kit was used as directed by the manufacturer, and tissues were incubated for 45 min at RT. The DAB reagent was prepared as instructed by the manufacturer and applied to tissues on TMA slides for 2 -10 min until brown color developed. TMAs were stained with hematoxylin, dehydrated in 50%, 70%, 95%, and 100% ethanol, and mounted with Permount. Pancreatic cancer tissue was used as a positive control. Staining was evaluated by A.K.-B. and L.R., who were both blinded to the experimental outcomes of the study. Staining was scored based on the intensity and percentage of positive cells. Intensity of staining was "0" for negative samples, "1" for weakly positive samples, "2" for moderately positive samples, and "3" for highly positive samples. Overall scores were derived as the intensity score multiplied by the percentage. Staining was assessed separately in the cytoplasm and the membrane.
Cell transfection and generation of stable cell lines
PA-1 cells were cultured to 80% confluence and transfected with either CX 3 CR1-specific GFP-tagged shRNA construct or scrambled GFP-tagged shRNA construct (Origene Technologies) using DharmaFECT according to the manufacturer's instructions. Selection of the clones was performed with puromycin and green fluorescence as suggested by the manufacturer.
Immunofluorescence staining
Cells were cultured on glass coverslips to 50-70% confluence, fixed, permeabilized with 0.01% Triton X-100, and blocked in goat serum. Mouse monoclonal CK-14 (Cat# ab49747) antibody was used at a dilution of 1:50. Cells were incubated with the primary antibodies for 1 h at room temperature (22°C). The cells were then incubated with secondary Alexa555-conjugated anti-mouse antibodies (1:500) for 1 h at RT in the dark. 4' ,6-Diamidino-2-phenylindole (DAPI) was added to the secondary antibody solution to a final concentration of 10 μg/ml 10 min prior to the end of the incubation period. Cells were washed, air dried, and mounted on glass slides using ProlongGold (Invitrogen, Carlsbad, CA). Fluorescent imaging was performed using a Zeiss AxioObserverD.1 fluorescent microscope.
Western blotting
Western blotting analysis was used to detect the expression of CK14, CK18, CX 3 CR1, CX 3 CL1, actin, and β-tubulin in PA-1. This procedure was performed as previously described [8, 14, 15] Antibodies were used at the following dilutions: 1:500 mouse anti-human-CK14 or CK18, or CX 3 CL1, rabbit anti-human CX 3 CR1 (Abcam ab8020) and 1:200 mouse anti-human-β-tubulin or goat antihuman actin in 3% BSA in a solution of 50 mM tris-buffered saline, pH 7.4, 150 mM NaCl, and 0.05% Tween-20 (TBST). Immunoreactive bands were visualized with anti-(mouse-IgG)-peroxidase, anti-(goat-IgG)peroxidase, and anti-(rabbit-IgG)-peroxidase (Sigma, St. Louis, MO) (1:1000 in 3% BSA in TBST), and enhanced chemiluminescence was read using Chemidoc (Bio-Rad) and Bio-Rad Chemidoc ImageReader software.
Results

CX 3 CR1 is expressed in specimens of ovarian teratoma
According to our previous observations CX 3 CR1 was expressed in cells comprising ovarian teratoma tissue specimens [8] , although the number of specimens was very limited in order to be able to draw any conclusions.
In the present study we aimed to expand this observation on a larger number of ovarian teratoma specimens and determine the predominant cell type(s) positive for CX 3 CR1. Thus, we tested expression of CX 3 CR1 using a tissue microarray containing 68 specimens of mature ovarian teratoma, 10 specimens of immature teratoma, and 2 cases of monodermal teratoma. Interestingly, we have found that skin keratinocytes represent the most predominant CX 3 CR1-positive cell type, which was present in 38% of tested cases of mature ovarian teratoma ( Table 1 , Figure 1 ). The next most common CX 3 CR1-positive types of cells in the tested cases of dermoid cyst were those comprising the pilosebaceous unit of the skin assembled of sebaceous gland and hair follicle (Table 1, Figure 1 ). Specimens of ovarian teratoma were examined for CX 3 CR1 expression by immunohistochemistry. Brown -CX 3 CR1; bluehematoxylin. Images were generated using an Aperio ScanScope digital slide scanner. Magnification -5×. A region outlined by a dotted line is shown at 20× magnification. Cells of the sebaceous gland, hair follicle, and skin are indicated. Other CX 3 CR1-positive cell types in the order of diminution included lymphatic, apocrine, adipose, thyroid, respiratory epithelial, peripheral nervous, endothelial, and eccrine ( Table 1) . Cases of tested immature ovarian teratoma were characterized by the presence of CX 3 CR1-positive brain, lymphatic, respiratory epithelial, adipose, and sebaceous cells (Table 1) . Two tested monodermal teratomas consisted of CX 3 CR1-positive thyroid and lymphatic tissues, respectively (Table 1) . Thus, our data suggest that skin keratinocytes are the predominant type of CX 3 CR1-positive cells in the tested specimens of mature ovarian teratomas.
CX 3 CR1 is expressed in fetal tissues
Further we wished to determine CX 3 CR1-positive cells undergoing the normal development. We tested both male and female fetal tissues aged 5 months in utero. We found that the majority of epithelial cells, including skin keratinocytes, were CX 3 CR1-positive (Table 2 ). Hence, CX 3 CR1-positive skin cells are present not only within abnormally differentiated tissues, such as mature ovarian teratomas, but also in the normally developing skin.
CX 3 CR1 is required for keratinocyte differentiation
Based on our observations regarding CX 3 CR1 expression in both normally and abnormally developing keratinocytes, we hypothesized that CX 3 CR1 may be important for cell differentiation into the epidermal lineage. Thus, we tested the requirement for CX 3 CR1 in keratinocyte differentiation using a cell culture model. Ovarian teratocarcinoma cell line PA-1 has been established from the ascites of a patient with malignant ovarian teratoma [16] . Chromosomal analysis had suggested that these cells have a heterozygous origin and derived at a stage prior to the first meiotic division [17] . Several studies have shown that PA-1 is capable of differentiation into diverse cell lineages at the appropriate culture conditions [16, 18, 19] . Based on many similarities between the teratocarcinoma cells and early embryonic cells, the former has been used to study processes of differentiation [19, 20] . Using gene specific shRNA constructs, we downregulated CX 3 CR1 in PA-1 cell line (Figure 2A ). Further we cultured both CX 3 CR1sh-PA-1 and the control cells transfected with a scrambled shRNA construct on Matrigel in the presence and absence of 0.5 nM BMP-4 for 2 weeks. Expression of cytokeratin 14 (CK14) and cytokeratin 18 (CK18) was analysed with immunofluorescence microscopy and Western blotting ( Figure 2B,C) .
We observed that only PA-1 transfected with scrambled shRNA and cultured in BMP-4-supplemented media expressed significantly higher levels of CK14 compared to scrambled shRNA PA-1 or CX 3 CR1 shRNA PA-1cultured in the absence of BMP-4, as well as CX 3 CR1 shRNA PA-1 cultured in the presence of BMP-4 ( Figure 2B ,C). In opposite, scrambled shRNA PA-1 or CX 3 CR1 shRNA PA-1cultured in the absence of BMP-4, as well as CX 3 CR1 shRNA PA-1 cultured in the presence of BMP-4 expressed higher levels of CK18 compared to scrambled shRNA PA-1 cultured in the presence of BMP-4 ( Figure 2C ). PA-1 expressed fractalkine ligand (CX 3 CL1) necessary for the receptor (CX 3 CR1) activation ( Figure 2D ). These data suggest that CX 3 CR1-positive PA-1 cells are able to proceed toward differentiation into skin keratinocytes in the presence of BMP-4 and begin expressing a marker of stratified epithelium CK14, while the loss of CX 3 CR1 restricts differentiation and the cells remain CK18-positive simple-epithelial cells.
Discussion
Our findings demonstrate that cells of the skin lineage comprise the most predominant CX 3 CR1-positive cell type within the specimens of ovarian teratoma. Mature skin is a predominant tissue found in mature ovarian teratomas [21] . Our findings also show that normally developed keratinocytes are CX 3 CR1-positive. Importantly, our findings suggest that CX 3 CR1 could be an important player in keratinocyte differentiation. Our data indicate that teratocarcinoma cell line PA-1 expressed a basal keratinocyte marker CK14 when cultured on Matrigel in the presence of BMP-4. In opposite, cells with silenced CX 3 CR1 and those cultured in the absence of BMP-4 expressed CK18 specific for simple nonstratified epithelium. The role for CX 3 CR1 in skin differentiation has not been described before, although, the role of this receptor in skin wound healing has been reported [22] . Our findings could be potentially important, as skin is the largest organ of the human body. Many pathological conditions and injuries require regeneration of the skin, and affecting the CX 3 CR1-dependent pathway could be one way to achieving faster skin formation from cells capable of differentiation. Thus, the studies of the role of CX 3 CR1 in keratinocyte differentiation need to be expanded further to include more extensive studies on other abnormally differentiating teratoma cell lines, as well as normally differentiating embryonic stem cells. Furthermore, we observed that CX3CR1 is expressed in other developing tissues, as indicated in Table 2 , thus, it is possible that this receptor could be important for the development of those tissues as well. In fact, a role for the fractalkine axis in osteoclasts differentiation has been reported, whereby CX 3 CL1-expressing osteoblasts regulate differentiation of CX 3 CR1positive osteoclast precursors [12] . Hence, more rigorous future studies of the role of CX 3 CR1 in development and differentiation are required.
Conclusions
Here we present that fractalkine receptor is expressed by skin cells in specimens of human ovarian teratoma and fetus and is required for epidermal lineage differentiation. This information sheds light on the ovarian pathology, dermoid cyst, and outlines possible mechanisms of cell differentiation within this benign formation. As the fractalkine receptor has recently emerged as a novel potential therapeutic target against many debilitating diseases, it is important to remember its role in cell differentiation when applying future antifractalkine therapies.
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